Press Release
InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Mantle Cell Lymphoma in Singapore
22 Nov, 2022
82
4042
InnoCare Releases 2022 Third Quarter Results: Star Board Listing for Long-term Growth and Rapid Increase of Orelabrutinib Sales
14 Nov, 2022
148
4033
10 Studies on Orelabrutinib Selected at the Upcoming 64th Annual Meeting of ASH
08 Nov, 2022
74
4030
InnoCare Announces First Adolescent Patient Dosed in Clinical Trial of pan-TRK Inhibitor ICP-723 in China
31 Oct, 2022
86
4021
InnoCare Completes Initial Public Offering on the STAR Market of the Shanghai Stock Exchange in China
21 Sep, 2022
143
3982
InnoCare Announces Approval of Clinical Trial of BCL2 Inhibitor ICP-248 in China
13 Sep, 2022
98
3948
InnoCare Announces First Patient Dosed in Phase II Registrational Trial of Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in China
09 Sep, 2022
104
3945
InnoCare Announces Priority Review of Orelabrutinib for the Treatment of R/R MZL by NMPA
06 Sep, 2022
97
3942
InnoCare Announces the Acceptance of the Biologics License Application for Tafasitamab in Combination with Lenalidomide for Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Hong Kong
31 Aug, 2022
96
3938
InnoCare and Keymed Jointly Announce Approval of Clinical Trial of CCR8 Monoclonal Antibody CM369
24 Aug, 2022
86
3935